OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions

MENLO PARK, Calif.--(BUSINESS WIRE)-- #ADA2026--At ADA 2026, OrsoBio to share clinical and preclinical data highlighting potential multi-system benefits of mitochondrial protonophore mechanism.